Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Molecule May Lead to Development of New Spinal Muscular Atrophy Therapy
Uncategorized

Molecule May Lead to Development of New Spinal Muscular Atrophy Therapy

By Roger AndersonAug 6, 2013
Share
Facebook Twitter Email
Christine DiDonato, PhD, assistant professor in pediatrics-human molecular genetics, demonstrated the effectiveness of a new drug as a treatment for spinal muscular atrophy, while also helping to identify the correct dose and exposure for a clinical trial.

New Northwestern Medicine® research has provided another building block in the treatment of one of the leading causes of infant and early childhood mortality in the developed world, spinal muscular atrophy (SMA). 

Although the genetic cause of SMA is well understood, there exists no cure for the hereditary disease, which affects the spinal cord and causes muscle weakness and breathing problems. Published in Human Molecular Genetics in coordination with a paper from Charlotte Sumner, MD, at Johns Hopkins University, the research by Christine DiDonato, PhD, assistant professor in pediatrics-human molecular genetics, has helped set the stage for future clinical approaches. 

“Collectively, our work represents another step forward in the development of therapeutic candidates for the treatment of SMA, which have now reached testing in human subjects,” said DiDonato, a member of the Human Molecular Genetics Program of the Ann and Robert H. Lurie Children’s Hospital of Chicago Research Center. “These findings are exciting, as our publications provide strong pre-clinical efficacy of the drug RG3039 across three SMA models of varying disease severity.”

SMA is caused by insufficient levels of the survival motor neuron protein. The goal of early SMA drug discovery programs has been to identify small molecules that will encourage the production of sufficient levels of the protein, thereby improving motor neuron function. The molecule RG3039 has proven to be a promising candidate, and the studies led by DiDonato provided dose selection and exposure estimates for the first studies of RG3039 in humans.  

“Our results also showed increased survival as well as functional benefits in mouse models,” DiDonato said. “The functional benefits included muscle strength and endurance, which are greatly reduced in SMA patients.”  

Starting her research more than two decades ago, before the gene responsible for the disease was known, DiDonato is especially excited that a major pharmaceutical company has licensed RG3039 for further clinical development. 

“We’re very happy that our research was able to assist in the development of the molecule and contribute to dosage estimates,” she said. “It is reassuring that our results mirrored independent findings as we move closer to developing therapies for SMA patients.” 

DiDonato’s work was supported by the Families of SMA, Repligen Corporation, and the National Institutes of Health. 

Families of SMA funded and directed the preclinical development of RG3039, providing the investment for the first drug discovery program ever conducted specifically for the disease. In January, Pfizer licensed the program to develop potential treatments.

Patient Care Research
Share. Facebook Twitter Email

Related Posts

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023
Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Comments are closed.

Latest News

Self-Powered Wireless Implant Delivers Medication, Then Dissolves

Mar 30, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

The Future of IgE-Mediated Allergy Research and Treatments

Mar 29, 2023

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.